[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560307":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":24,"studyPopulation":27,"armGroups":24,"interventions":24,"overallOfficials":24,"centralContacts":28,"locations":37,"responsibleParty":50,"collaborators":24,"id":55,"slug":24,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":24,"enrollmentInfo":63,"targetDuration":24,"studyType":66,"phases":24,"briefSummary":67,"conditions":68,"keywords":24,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University College London Hospitals","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":24},[9,13],{"measure":10,"description":11,"timeFrame":12},"Demographics, comorbidities and environmental exposures of participants","From review of electronic health records","Comorbidities and environmental exposures at diagnosis (approximately up to 156 weeks prior to diagnosis)",{"measure":14,"description":11,"timeFrame":15},"Participant pathways including presentation mode and symptoms","Presentation mode and symptoms at time of diagnosis (approximately up to 52 weeks prior to diagnosis)",[17,20],{"measure":18,"description":11,"timeFrame":19},"Participant outcomes such as cancer stage, treatment, mortality","Cancer stage at time of diagnosis, treatment and mortality through study completion (likely 5 years)",{"measure":21,"description":22,"timeFrame":23},"Measurement of modifiable and non-modifiable factors associated with LCINS","To be determined","Through study completion (likely 5 years)",null,{"allocation":24,"interventionModel":24,"interventionModelDescription":24,"primaryPurpose":24,"observationalModel":26,"timePerspective":6,"maskingInfo":24},"COHORT","This study will aim to recruit participants who have been diagnosed or treated with primary lung cancer at any participating study site.",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Neal Navani, PhD","CONTACT","020 7679 2000","n.navani@ucl.ac.uk",{"name":35,"role":31,"phone":32,"phoneExt":24,"email":36},"Sindhu Naidu, MBBS","s.naidu@ucl.ac.uk",[38],{"facility":39,"status":40,"city":41,"state":24,"zip":24,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":24},"University College London Hospital","RECRUITING","London","United Kingdom","UK",{"type":45,"coordinates":46},"Point",[47,48],-0.12574,51.50853,{"lat":48,"lon":47},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":54,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Neal Navani","Professor of Respiratory Medicine","University College, London","100560307",false,"NCT06575439","An Observational Study of Predictors and Outcomes of Lung Cancer in Never-smokers in the UK","OLIVE","Inclusion Criteria:\n\n* All adult participants from age of 18 who are diagnosed or treated with primary lung cancer through radiology or histology at any participating study site\n\nExclusion Criteria:\n\n* Participants who have ever smoked cigarettes or tobacco will be excluded; this is defined as:\n\n  * More than 100 cigarettes or 75g tobacco in their lifetime\n  * Those who have received a prescription for nicotine replacement therapy\n* For prospective participants, those who cannot consent will be excluded","ALL","18 Years",{"count":64,"type":65},225,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to improve the early detection of lung cancer in adults who have smoked less than 100 tobacco cigarettes (\"never-smokers\") in the United Kingdom. The main questions it aims to answer are:\n\n* To describe characteristics such as demographics, co-morbidities and environmental exposures\n* To describe participant pathways including presentation mode and symptoms to understand if earlier diagnosis would be possible\n* To describe participant outcomes such as cancer stage, treatment and mortality\n* To quantitatively or qualitatively measure modifiable and non-modifiable factors that may be associated with LCINS including environmental measures, blood tests and genomic data.\n\nParticipants will currently have no change to their usual care.",[69],"Lung Cancer","2024-12-08",{"date":72,"type":73},"2024-12-12","ACTUAL",{"date":75,"type":73},"2024-09-17",{"date":77,"type":65},"2029-09",{"name":5,"class":6},1]